INS and liver disorder: Thus, it is intriguing to propose that the amelioration of insulin sensitivity by the conversion of immunosuppression from TAC to CyA slows down the natural course of HCV-related liver disease and improves viral response to anti-HCV treatment as was shown for insulin-sensitizer pioglitazone in patients with HCV genotype 4 [30].